INTRODUCTION

Acute respiratory infections cause approximately four million deaths per year globally, being the leading cause of death in developing countries. Streptococcus pneumoniae is the most common etiologic agent of community-acquired bacterial respiratory tract infections. Invasive pneumococcal disease (IPD) accounts for a portion of all S. pneumoniae infections, being defined as the contamination of sterile body fluids with this agent, that is, as the isolation of S. pneumoniae from cultures of blood, cerebrospinal fluid, pleural fluid, or other normally sterile body sites.

IPD has high socioeconomic costs, with increased (acute and late) morbidity and mortality, especially in susceptible populations (children, the elderly, patients with cardiac comorbidities, patients with pulmonary comorbidities, and immunosuppressed patients in general). IPD continues to be the leading vaccine-preventable cause of death in children under 5 years of age, even with the significant change in the epidemiology of this disease after the implementation of routine vaccination in Australia and in western European countries.

In the USA, after the marketing of the 7-valent pneumococcal conjugate vaccine in the 2000s, there was a significant reduction in the number of cases of IPD in children up to 5 years of age and in adults over 50 years of age because of the herd effect. There was also a replacement of serotypes in the community by others not previously included. With the introduction of the 13-valent pneumococcal conjugate vaccine (PCV13) in that same country, the number of hospitalizations for IPD in children under 5 years of age was further reduced, and there was also some effect on hospitalizations for IPD among some adult age groups.

Therefore, the present study was carried out to evaluate the microbiological characteristics of community-acquired invasive S. pneumoniae strains in inpatients at a tertiary care hospital in order to determine the theoretical coverage of the pneumococcal vaccines currently available in Brazil—PCV13 and 23-valent pneumococcal polysaccharide vaccine (PPV23)—as well as to quantify possible prevention. It is important to conduct studies to determine the serotypes...
of IPD and the theoretical coverage of the available vaccines so that new formulations of these vaccines can eventually be developed, including serotypes that have not yet been covered, herd effect can be determined, and the serotypes involved in IPDs in each location can be identified.

The difference between the two vaccines lies in the type of immunity conferred: PPV23 bases its ability to confer immunity on the pneumococcal polysaccharide capsule (B cell-dependent immune response), whereas PCV13 elicits a T cell-dependent immune response (long-term immune memory). (19) Chemical and serological differences between capsules are the basis for grouping pneumococci into different serotypes. (11,12) Each serotype is distinguished by the chemical structure of the capsule, by immune response, that is, by the ability to react with specific antibodies against the capsular antigen, and by other related specific mutations. However, not all of the more than 90 pneumococcal serotypes identified cause disease. Some serotypes are more strongly related to bacterial resistance, and others are more strongly related to deaths and invasive disease. (13) PCV13 includes serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F. PPV23 includes all serotypes included in PCV13 except serotype 6A, plus another 11 serotypes: 2, 8, 9N, 10A, 11A, 12F, 15B, 17F, 20, 22F, and 33F.

In view of these considerations, the present investigation was devised to find some answers on a more local level in an attempt to determine similarities and differences from what is already known on this subject at the regional and national level.

METHODS

This was a cross-sectional, descriptive, analytical study involving inpatients at a tertiary care hospital in the city of Porto Alegre, Brazil, in whom laboratory testing of sterile body fluids detected S. pneumoniae. All specimens were collected between January 2005 and December 2016. Antimicrobial susceptibility was assessed using the Kirby-Bauer method on Mueller-Hinton agar (bioMérieux, Marcy l’Étoile, France) supplemented with blood, and the antimicrobials tested included erythromycin, levofloxacin, oxacillin, sulfamethoxazole/trimethoprim, and vancomycin. All cases in which a halo of inhibition ≥ 20 mm was observed for oxacillin (1 µg) were considered susceptible to penicillin. Those in which a halo of inhibition ≤ 19 mm was observed for oxacillin were submitted to penicillin ETEST® (bioMérieux) to determine the minimum inhibitory concentration. The criteria for determining the antibiotics to be tested, as well as the criteria for interpreting halos of inhibition and susceptibility or resistance to penicillin after ETEST®, followed the recommendations of the Clinical and Laboratory Standards Institute. (14) Clinical and demographic data were collected by review of patient medical records.

Vaccine coverage data were not available from medical records, so we theorized vaccine coverage and correlated it with the serotypes identified in the sample, that is, we sought to relate each identified serotype to the potential coverage of the vaccines available in Brazil. Pneumococcal cultures were sent to the Adolfo Lutz Institute, in the city of São Paulo, Brazil, via the Central Laboratory of the State of Rio Grande do Sul, for serotyping. A decision was made to include patients with immunosuppression in the study sample, because the objective was to determine whether the serotypes identified in the sample were covered by the vaccines available. Categorical variables were expressed as frequencies and proportions, symmetric quantitative variables were expressed as means and standard deviations, and asymmetric quantitative variables were expressed as medians and interquartile ranges (IQRs). Quantitative data were compared by analysis of homogeneity of variance (Cochran’s test), whereas nominal data were compared by using McNemar’s test. The level of significance was set at α = 0.05. Data were analyzed with SPSS Statistics, version 21.0 (IBM Corporation, Armonk, NY, USA). The study was approved by the Scientific Committee of the School of Medicine and the Research Ethics Committee of the Pontifical Catholic University of Rio Grande do Sul (Protocol no. 56187816.5.0000.5336).

RESULTS

A total of 147 pneumococcal strains were initially considered for analysis, but only 118 were analyzed (losses included 15 dead strains, 6 missing samples, 5 contaminated samples, and 3 samples with pending results). The most common serotypes were, in decreasing order, 19A, 3, 12F, 8, 14, and 11A (Figure 1). Figure 2 presents the proportion of serotypes in the study sample.

The patients studied were mostly male (n = 66; 55.9%), with a median age of 57 years (IQR: 33-72 years). The most common manifestation was pneumonia (n = 90; 76.3%), followed by meningitis (n = 12; 10.2%). The most common culture was blood culture (n = 101; 85.6%), followed by cerebrospinal fluid culture (n = 15; 13.7%). Overall mortality was 33.1% (n = 39). Immunosuppressed patients (HIV and/or neoplasm and/or use of corticosteroids and/or use of immunosuppressants) accounted for 28.8% (n = 34) of the sample. In the study population, 19 patients (16.1%) had pulmonary comorbidities, and 58 (49.2%) had previous hospital admissions. ICU admission and mechanical ventilation (MV) were necessary in 41 cases (34.7%) and 28 cases (23.7%), respectively (Table 1).

When comparing the presence/absence of comorbidities as a risk factor for mortality, as well as for ICU admission, MV, and tracheostomy, we found no statistically significant differences (Table 2). There was no significant correlation between mortality and the different serotypes.

In terms of antimicrobial susceptibility, the proportion of samples resistant to sulfamethoxazole/trimethoprim, erythromycin, penicillin, and levofloxacin was 37.3%,
17.8%, 9.3%, and 1.7%, respectively. There were no cases of resistance to vancomycin. Multiple comparisons with McNemar’s test showed that the strains were less susceptible to sulfamethoxazole/trimethoprim and more susceptible to vancomycin and levofloxacin.

Table 3 presents the theoretical coverage of PCV13 and PPV23 alone, as well as in combination, in relation to mortality. No statistically significant differences were detected (p = 0.508).

**DISCUSSION**

The present study evaluated data on serotyping of pneumococci associated with IPD in inpatients at a hospital that services a considerable portion of the population with IPD in a regional capital city in Brazil. Analysis of pneumococcal serotypes was possible in 118 (80.27%) of the cases in the total sample.

The most common serotypes in our sample were, in decreasing order, 19A, 3, 12F, 8, 14, and 11A, with serotype 19A accounting for 12.7% of the total sample. The literature on Brazilian strains tends to indicate serotype 14 as the most common. (15-19) Usually, serotypes associated with increased mortality include serotypes 3, 6A, 6B, 8, 19F, 23F, and 6C, whereas those associated with decreased mortality include serotypes 23A, 35B, and 35F. (20) In the cases analyzed...
here, there were no significant differences between the serotype and the occurrence of death. In Brazil, the frequency of serotype 20B has been increasing, but its detection rate was low in the sample studied here.

In the present study, as shown in Table 3, the theoretical coverage of PPV23 alone and of PCV13 plus PPV23 was 31.4% and 50.8%, respectively. This means that, theoretically, patients receiving the vaccine combination would have a reduction in the number of IPD cases associated with the serotypes identified in the present study. Andrade et al. and Mott et al. reported a theoretical coverage of PCV13 of 94.1% and 64.5%, respectively, which is well above our results.

In 1988, the first case of resistance to penicillin was reported in Brazil, and, in 2006, Camargos et al. published that the 7-valent pneumococcal conjugate vaccine covered 89% of penicillin-resistant pneumococci and could then help reduce the spread of these strains, thereby decreasing the need for antibiotics. Regardless of the existence of vaccines, increased pneumococcal resistance to penicillin has become worrisome, and, in the future, therapeutic failure may occur when starting empirical antimicrobial therapy.

As early as 2006, Zettler et al. reported a prevalence of penicillin-resistant strains of 22.8% in cultures of sterile body fluids and sputum. Other Brazilian authors reported finding resistance to penicillin in 13.3% of the strains and resistance to sulfamethoxazole/trimethoprim in 37.7% to 80.0% of the strains. In the present study, these resistances were 9.3% and 37.3%, respectively, and there was no resistance to vancomycin. Serotypes 9 and 14 appear to be associated with greater resistance to penicillin, a finding that was not observed in the sample studied here.

As has been shown in other studies, the most common manifestation of IPD was community-acquired pneumonia (n = 90; 76.3%). The pneumococcus is most commonly isolated from blood cultures, a finding similar to that of our study (n = 101; 85.6%). When studying comorbidities in the present sample in terms of mortality and need for ICU care and/or MV, we detected no significant differences, and overall mortality in our sample was 33.1% (n = 39).

A crucial part in the treatment of (invasive or noninvasive) pneumococcal disease is the use of antimicrobials, which may be decisive in the course and prognosis of the disease. Some authors have suggested that surveillance of only cases that required hospitalization probably underestimates the true socioeconomic costs of IPD. The path to reduce the high morbidity, mortality, and socioeconomic costs of the disease must be through prevention.
There is as yet no consensus as to whether it would be possible to replace PPV23 with PCV13 in adults, it being considered that, even without having the highest number of serotypes, PCV13 would be better for the adult population because it produces more antibodies in the long term. Some authors disagree with this position, emphasizing that cost-effectiveness studies of vaccination of adults with PCV13 (rather than with PPV23) have been influenced by biases. Among these biases are the low herd effect produced by the use of PCV13 in children and the poor prevention against community-acquired pneumonia resulting from the use of PPV23 in adults with any immunosuppression.

Another point to be confirmed is the apparent increased frequency of IPD caused by nonvaccine serotypes in some places, including Brazil. This is believed to be due to the increased number of vaccinated children, with the consequent herd effect, and the progressive replacement of vaccine serotypes with nonvaccine serotypes in the etiology of cases.

The present study was aimed at finding some answers on a more local level, that is, it sought to determine whether the serotypes in our region would match those in other parts of Brazil, establishing a connection between these findings and the theoretical coverage of the two currently available pneumococcal vaccines. Our results reinforce the need for an intensive policy of pneumococcal vaccination not only of children but also of adults 18 years of age or older with comorbidities, in order to reduce the still very high morbidity and mortality associated with IPD, especially in developing countries.

**ACKNOWLEDGMENTS**

The authors are grateful to Professor Maria C. Brandleione at the Adolfo Lutz Institute for her support to this study. The authors are also grateful to Vany Pagnussatti, a microbiologist at the Pontifical Catholic University of Rio Grande do Sul Hospital São Lucas Microbiology Laboratory, for performing the pneumococcal cultures.

**REFERENCES**

1. Ferkol T, Schraufnagel D. The global burden of respiratory disease. Am J Respir Crit Care Med. 2014;113(4):404-6. https://doi.org/10.1513/AnnalsATS.201311-045PS
2. Griffin MR, Zhu Y, Moore MR, Whitney CG, Grijalva CG. U.S. hospitalizations for pneumonia after a decade of pneumococcal vaccination. N Engl J Med. 2013;369(2):155-63. https://doi.org/10.1056/NEJMc1209185
3. Weite T, Torres A, Nathwani D. Clinical and economic burden of community-acquired pneumonia among adults in Europe. Thorax. 2012;67(1):71-9. https://doi.org/10.1136/thoraxjnl-2009-129502
4. Burgos J, Lujan M, Larrosa MN, Fontanals D, Bermudo G, Planes AM, et al. Risk factors for respiratory failure in pneumococcal pneumonia: the importance of pneumococcal serotypes [abstract]. Eur Respir J. 2014;43(5):545-50. https://doi.org/10.1183/09031936.00050143
5. Burgos J, Lujan M, Larrosa MN, Pedro-Botet ML, Fontanals D, Quesada MD, et al. The problem of early mortality in pneumococcal pneumonia: a study of risk factors. Eur Respir J. 2015;46(2):561-4. https://doi.org/10.1183/09031936.0034415
6. Flego KL, Truman G, Sheppard V, Gilmour RE. Invasive pneumococcal disease in western Sydney, 2002-2010. N S W Public Health Bull. 2011;22(11-12):219-21. https://doi.org/10.1071/NB11012
7. Tin Tin Htar M, Christopoulou D, Schmitt HJ. Pneumococcal serotype evolution in Western Europe [abstract]. BMC Infect Dis. 2016;16(1):416. https://doi.org/10.1186/s12879-015-1147-x
8. Huang SS, Johnson KM, Ray GT, Wroe P, Lieu TA, Moore MR, et al. Healthcare utilization and cost of pneumococcal disease in Western Europe [abstract]. BMC Infect Dis. 2015;15:419. https://doi.org/10.1186/s12879-015-1147-x
9. Simonsen L, Taylor RJ, Schuck-Paim C, Lustig R, Haber M, Clugman KP. Effect of 13-valent pneumococcal conjugate vaccine on admissions to hospital 2 years after its introduction in the USA: a time series analysis. Lancet Respir Med. 2014;2(6):387-94. https://doi.org/10.1016/S2213-2600(14)70074-5
10. Ferkol T, Schraufnagel D, The global burden of respiratory disease. Am J Respir Crit Care Med. 2014;113(3):404-6. https://doi.org/10.1513/AnnalsATS.201311-045PS

### Table 3. Theoretical vaccine coverage.

| Vaccine coverage | Total sample (N = 118) | Death (n = 39) | Non-death (n = 77) | p |
|------------------|-----------------------|---------------|-------------------|---|
| PCV13 alone      | 1 (0.8)               | 1 (2.6)       | 0 (0.0)           |   |
| PPV23 alone      | 37 (31.4)             | 12 (30.8)     | 25 (32.5)         | 0.508 |
| PCV13 plus PPV23 | 60 (50.8)             | 19 (48.7)     | 41 (53.2)         |   |
| No coverage      | 20 (16.9)             | 7 (17.9)      | 11 (14.3)         |   |

PCV13: 13-valent pneumococcal conjugate vaccine; and PPV23: 23-valent pneumococcal polysaccharide vaccine (PPV23). *Values expressed as n (%). †Two patients with unknown outcome status (no vaccine coverage). ‡Serotype 6A. §Serotypes 3, 8, 9N, 10A, 11A, 12F, 15B, 17F, 20, 22F, and 33F.
